These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 27720325)

  • 21. Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.
    Yuan J; Simpson RD; Zhao W; Tice CM; Xu Z; Cacatian S; Jia L; Flaherty PT; Guo J; Ishchenko A; Wu Z; McKeever BM; Scott BB; Bukhtiyarov Y; Berbaum J; Panemangalore R; Bentley R; Doe CP; Harrison RK; McGeehan GM; Singh SB; Dillard LW; Baldwin JJ; Claremon DA
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4836-43. PubMed ID: 21741239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors.
    Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Sugita C; Miyazaki S; Tamaki K; Matsui Y; Takahashi M; Nagayama T; Nagai Y; Inoue S; Nishi T
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7677-82. PubMed ID: 23122821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.
    Lawhorn BG; Tran T; Hong VS; Morgan LA; Le BT; Harpel MR; Jolivette L; Diaz E; Schwartz B; Gross JW; Tomaszek T; Semus S; Concha N; Smallwood A; Holt DA; Kallander LS
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4838-4843. PubMed ID: 28985999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fragment-Based Protein-Protein Interaction Antagonists of a Viral Dimeric Protease.
    Gable JE; Lee GM; Acker TM; Hulce KR; Gonzalez ER; Schweigler P; Melkko S; Farady CJ; Craik CS
    ChemMedChem; 2016 Apr; 11(8):862-9. PubMed ID: 26822284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico fragment-based discovery of DPP-IV S1 pocket binders.
    Rummey C; Nordhoff S; Thiemann M; Metz G
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1405-9. PubMed ID: 16321524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NEW RENIN INHIBITORS - STABILITY AND ACTIVITY DETERMINATION. PART IV.
    Marszalek D; Goldnik A; Winiecka I; Jaworsk P; Mazurek Aleksander P
    Acta Pol Pharm; 2017 Mar; 74(2):393-399. PubMed ID: 29624244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.
    Grädler U; Schwarz D; Blaesse M; Leuthner B; Johnson TL; Bernard F; Jiang X; Marx A; Gilardone M; Lemoine H; Roche D; Jorand-Lebrun C
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126717. PubMed ID: 31635932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
    Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
    Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Barnes K; Johnson M; Hui Y; Turner J; Hu Y; Wagner E; Fan K; Olland A; Bard J; Robichaud AJ
    J Med Chem; 2009 Oct; 52(20):6314-23. PubMed ID: 19757823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
    Zhang X; Song F; Kuo GH; Xiang A; Gibbs AC; Abad MC; Sun W; Kuo LC; Sui Z
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4762-7. PubMed ID: 21767952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental Active-Site Mapping by Fragments: Hot Spots Remote from the Catalytic Center of Endothiapepsin.
    Radeva N; Krimmer SG; Stieler M; Fu K; Wang X; Ehrmann FR; Metz A; Huschmann FU; Weiss MS; Mueller U; Schiebel J; Heine A; Klebe G
    J Med Chem; 2016 Aug; 59(16):7561-75. PubMed ID: 27463859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel 7-azaindoles as PDK1 inhibitors.
    Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.